Large B-cell lymphoma: is the future written in the blood?

The Lancet Oncology

Volumn 16, Issue 5, 2015, Pages 481-483

  Dawson, Sarah Jane ^a   Seymour, John F ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CIRCULATING TUMOR DNA; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; IMMUNOGLOBULIN; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

BLOOD ANALYSIS; CANCER PROGNOSIS; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DNA DETERMINATION; HUMAN; LARGE CELL LYMPHOMA; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VDJ RECOMBINATION; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; MALE; RADIOGRAPHY;

DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE;

EID: 84933670737     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70160-9     Document Type: Note

References (10)

1. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
2. Anker P, Mulcahy H, Chen XQ, Stroun M Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18:65-73.
3. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013, 368:1199-1209.
4. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
5. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014, 32:3059-3068.
6. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
7. Cheah CY, Hofman MS, Dickinson M, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Brit J Cancer 2013, 109:312-317.
8. Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015, published online April 2. http://dx.doi.org/10/1016/S1470-2045(15)70106-3.
9. Arnold A, Cossman J, Bakhshi A, Jaffe ES, Waldmann TA, Korsmeyer SJ Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med 1983, 309:1593-1599.
10. El Messaoudi S, Rolet F, Mouliere F, Thierry AR Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta 2013, 424:222-230.